Lineage Cell Therapeutics, Inc. (LCTX) Gross margin 2016–2024
Lineage Cell Therapeutics, Inc. (LCTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
96.5%FY2024 · since FY2016: 94.0% → 96.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | 96.5% | +4.0 pp |
| FY2023 | 92.5% | -2.6 pp |
| FY2022 | 95.0% | +27.9 pp |
| FY2021 | 67.2% | -11.8 pp |
| FY2020 | 78.9% | -9.4 pp |
| FY2019 | 88.3% | -5.7 pp |
| FY2018 | 93.9% | -1.2 pp |
| FY2017 | 95.1% | +1.2 pp |
| FY2016 | 94.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →